Market Exclusive

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) price target set to $40.00 by HC Wainwright

Analyst Ratings For Adamas Pharmaceuticals Inc (NASDAQ:ADMS)

Today, HC Wainwright set its price target on Adamas Pharmaceuticals Inc (NASDAQ:ADMS) to $40.00 per share.

There are 8 Buy Ratings, 2 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Adamas Pharmaceuticals Inc (NASDAQ:ADMS) is Buy with a consensus target price of $35.1250 per share, a potential 223.14% upside.

Some recent analyst ratings include


About Adamas Pharmaceuticals Inc (NASDAQ:ADMS)
Adamas Pharmaceuticals, Inc. discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease. The company's product candidates under development includes ADS-5102, which is in Phase III clinical trials for the treatment of multiple sclerosis walking impairment; and in Phase II clinical trials for additional indications, such as the treatment of wearing OFF and delaying motor complications in Parkinson's disease, tardive dyskinesia, Huntington's chorea, and Tourette syndrome, as well as non-motor disorders consisting of depression, and anti-psychotic induced weight gain. Its products under development also includes ADS-4101, a modified-release lacosamide that has completed Phase I clinical study for the treatment of partial onset seizures in patients with epilepsy. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

Recent Trading Activity for Adamas Pharmaceuticals Inc (NASDAQ:ADMS)
Shares of Adamas Pharmaceuticals Inc closed the previous trading session at 11.00 −0.89 7.49% with shares trading hands.

Exit mobile version